Ibrutnib in Older Patients With Mantle Cell Lymphoma

August 3, 2018
Brad S. Kahl, MD

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

Brad S. Kahl, MD, professor in the department of medicine at Washington School of Medicine at Siteman Cancer Center, discusses the use of ibrutinib (Imbruvica) in older patients with mantle cell lymphoma. This agent is currently being investigated in the frontline setting for patients not eligible for stem cell transplant.

SHINE is a larger trial that is fully enrolled, but the readout is not available yet. Patients in this trial were randomized to receive either bendamustine or rituximab (Rituxan), or a combination of bendamustine/rituximab plus ibrutinib. Ibrutinib was also continued as a post-remission therapy, according to Kahl.